Looking for AAPA Category 1 Pharmacology Credit? 5 Things Every PA Should Know

Maintaining your PA-C certification and state licensure requires a strategic approach to Continuing Medical Education (CME). While the NCCPA does not mandate a specific number of pharmacology hours for national certification, your state medical board likely does. For PAs with prescriptive authority, staying current on pharmacotherapeutics is not just a regulatory hurdle: it is a clinical necessity.

At CME Review Courses, we provide an efficient, PA-focused solution to meet these requirements. Our Pharmacology CME Review Course is specifically designed to maximize your time and your employer-provided CME budget.

Here are five things every Physician Assistant should know when looking for AAPA Category 1 Pharmacology credit.

1. State Requirements Drive the Need for Pharmacology CME

While the NCCPA requires 100 CME credits every two years (with at least 50 being Category 1), they do not specify the subject matter. However, state licensing boards are different. Many states require a minimum number of pharmacology hours for license renewal or to maintain prescriptive authority.

For example, Maryland requires at least 8 hours of pharmacology, while Massachusetts requires at least 4 hours for PAs with prescriptive authority. Ohio requires 12 hours of pharmacology from an accredited institution. Our Pharmacology CME Review Package offers 12 AAPA Category 1 Self-Assessment CME credits, ensuring you meet or exceed these state-specific thresholds in a single, comprehensive course.

2. The Self-Assessment Bonus Multiplier

Not all Category 1 credit is created equal. The NCCPA provides a significant incentive for completing Self-Assessment CME. When you log AAPA Category 1 Self-Assessment CME credits, the NCCPA applies a 50% bonus multiplier.

Because our pharmacology course is designated as Self-Assessment (AAPA Reference Number: CME-209464), the 12 credits you earn are recognized as 18 credits by the NCCPA. This is one of the most efficient ways to reach your 100-hour biennial goal while simultaneously satisfying state pharmacology mandates.

3. Maximizing Your CME Budget with Gift Card Add-Ons

Many PAs are provided with a dedicated annual CME allowance that is "use it or lose it." We offer a unique way to ensure you get the most value from these professional development funds. Our CME with Gift Card packages allow you to add an Amazon or Apple Gift Card ranging from $100 to $1500 to your purchase.

This allows you to acquire the necessary pharmacology or PANRE review materials while also obtaining a gift card that can be used for further educational tools, medical equipment, or technology to enhance your clinical practice.

4. Content Written by PAs for PAs

Generic pharmacology courses often fail to address the specific clinical scenarios PAs face daily. Our content is developed by physician assistants who understand the rigors of the profession. The course covers high-yield topics across multiple specialties, including:

• Cardiology and Neurology
• Emergency Medicine and Internal Medicine
• Orthopedics and Dermatology
• Psychiatry, OB/GYN, and Family Medicine

This ensures that the pharmacological principles you review are immediately applicable to your patient population, whether you work in a high-acuity ER or a busy primary care clinic.

5. Value for the Entire Healthcare Team

While our primary focus is the Physician Assistant, our pharmacology and PANRE review courses provide value across the clinical spectrum. Nurse Practitioners (NPs) can claim credit for AAPA Category 1 credits in many states. Physicians can also find value in our packages; while it counts as Category 2 CME for MDs/DOs, the clinical vignettes and drug reviews remain an excellent resource for board prep or general knowledge refreshers.

---

Pharmacology CME Review Course Details

• Price: $399.99 (Base Package)
• Credits: 12 AAPA Category 1 Self-Assessment CME Credits (Counts as 18 NCCPA credits)
• Access: 30 Months of online access
• Deliverables: Comprehensive online review and a 120+ Question Bank
• Gift Card Options: Available as an add-on from $100–$1500

---

Clinical Pharmacology Assessment

Practice Question 1

Your patient is a 64-year-old male with a history of chronic heart failure (HFrEF, EF 30%) and atrial fibrillation. He presents to the clinic for a routine follow-up. His current medications include lisinopril, carvedilol, and warfarin. During the exam, his HR is 88 bpm (irregular) and BP is 132/78 mmHg. He mentions he has started taking a new herbal supplement, St. John’s Wort, for mild depressive symptoms.

Which of the following describes the most likely pharmacological interaction in this patient?

A. Decreased efficacy of carvedilol due to CYP2D6 inhibition.
B. Increased risk of bleeding due to warfarin displacement from albumin.
C. Decreased therapeutic effect of warfarin due to CYP3A4 induction.
D. Potentiation of lisinopril-induced hyperkalemia.

Correct Answer: C. Decreased therapeutic effect of warfarin due to CYP3A4 induction.
St. John’s Wort is a potent inducer of several cytochrome P450 enzymes, most notably CYP3A4. Warfarin is a substrate for CYP3A4 (and 2C9). Induction of these enzymes increases the metabolism of warfarin, leading to lower serum levels and a subtherapeutic INR, which increases the patient's risk of thromboembolic events.

• A is incorrect because while carvedilol is a CYP2D6 substrate, St. John’s Wort's primary effect on warfarin is through induction, not inhibition.
• B is incorrect as St. John’s Wort induces metabolism rather than affecting protein binding to a clinically significant degree for warfarin.
• D is incorrect because St. John’s Wort does not have a known synergistic effect on potassium levels or the renin-angiotensin-aldosterone system.

Practice Question 2

Your patient is a 28-year-old female with a history of generalized anxiety disorder (GAD) currently managed with sertraline 50mg daily. She presents to the urgent care with a three-day history of "racing heart" and "shakiness." She was recently started on a medication for a "sinus infection" by another provider. Her vital signs are: HR 112 bpm, BP 145/92 mmHg, Temp 99.1°F, and SaO2 98% on room air. Physical exam reveals mild tremor and hyperreflexia.

Which of the following medications, if recently prescribed, most likely contributed to her current presentation?

A. Amoxicillin-Clavulanate
B. Tramadol
C. Azithromycin
D. Fluticasone nasal spray

Correct Answer: B. Tramadol
The patient’s symptoms (tachycardia, tremor, hyperreflexia) are suggestive of Serotonin Syndrome. Sertraline is an SSRI. Tramadol has dual mechanisms of action: it is an opioid agonist and also inhibits the reuptake of serotonin and norepinephrine. When combined with an SSRI, it significantly increases the risk of serotonin toxicity.

• A is incorrect as amoxicillin-clavulanate does not interact with the serotonergic system.
• C is incorrect because while azithromycin can prolong the QT interval, it does not typically cause serotonin syndrome.
• D is incorrect as intranasal fluticasone has minimal systemic absorption and no serotonergic activity.

Practice Question 3

Your patient is a 52-year-old male with a history of Type 2 Diabetes Mellitus and HTN. He is currently taking metformin 1000mg BID and chlorthalidone 25mg daily. His A1c is 8.4%. You decide to initiate an SGLT2 inhibitor.

Which of the following is a critical education point regarding the potential side effects of this medication class?

A. Risk of euglycemic diabetic ketoacidosis (DKA).
B. High risk of severe hypoglycemia when used with metformin.
C. Potential for significant weight gain.
D. Increased risk of peripheral edema.

Correct Answer: A. Risk of euglycemic diabetic ketoacidosis (DKA).
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) can cause euglycemic DKA, where the patient exhibits metabolic acidosis and ketosis despite having relatively normal blood glucose levels (<250 mg/dL). This is a critical safety point because patients may not realize they are in DKA if they only monitor their glucose.

• B is incorrect because SGLT2 inhibitors have a low risk of hypoglycemia when used as monotherapy or with metformin; the risk increases when combined with insulin or sulfonylureas.
• C is incorrect as SGLT2 inhibitors typically lead to weight loss due to caloric loss via glycosuria.
• D is incorrect as these medications are mild diuretics and generally reduce edema rather than cause it.

---

Whether you are preparing for the PANRE Review or simply need to fulfill your 12 hours of pharmacology CME, our courses provide the clinical depth and logistical efficiency you need. By choosing a self-assessment course, you earn 1.5x the credit with the NCCPA and stay current on the latest pharmacological guidelines.